British scientists have taken a crucial step in pandemic preparedness by vaccinating the first volunteers against the H5N1 bird flu strain, which poses a growing threat after decimating billions of poultry worldwide and jumping to mammals like U.S. cattle and South American seals.
The UK Health Security Agency assesses the human risk as very low for now, confined mostly to those handling infected animals, but experts warn of its potential to evolve. Since 2024, the World Health Organization has confirmed 116 human cases globally, many involving severe respiratory illness or eye infections treatable with antivirals such as oseltamivir.
Moderna’s experimental jab relies on mRNA technology proven during the Covid-19 crisis, enabling rapid tweaks and mass production as the virus mutates, unlike slower egg-grown alternatives that H5N1 often disrupts. The trial targets 4,000 participants, prioritising poultry workers and people over 65, with most sites in England and Scotland alongside U.S. collaborators.
Hampshire resident Clare Howard, who keeps chickens, was among the earliest to get the shot at a Southampton clinic. “It was quite easy and it could be something that ultimately proves incredibly important,” she said.
Dr Rebecca Clark, the national co-ordinating investigator at Blackpool’s Layton Medical Centre, highlighted the virus’s spread. The strain is “evolving and spreading across animal species.”
“Although it does not yet move easily between humans, we have to treat human-to-human transmission as a real possibility,” she said. “This trial is our proactive attempt to shield against that possibility, and any future pandemic that could emerge from it.”
If successful in proving safety and immune response, the vaccine could gain MHRA approval for stockpiling at Moderna’s Oxfordshire plant, capable of 100 million doses annually and scalable to 250 million in crisis.
Professor Lucy Chappell, the Department of Health and Social Care’s chief scientific adviser, called the effort “bolstering our pandemic resilience.” CEPI funded the £40 million trial after U.S. cuts, securing pledges for equitable global supply to avoid Covid-style inequities.
History cautions urgency: the 1918 flu killed 50 million, while H5N1 has claimed nearly half of 1,000 human cases since 2003. UK monitoring shows no local infections yet, but recent East Anglia outbreaks signal vigilance.